From local control to immune synergy: the evolving role of stereotactic body radiotherapy in the immunotherapy era of hepatocellular carcinoma [0.03%]
立体定向体放射治疗在肝细胞癌免疫治疗时代的角色演变：从局部控制到免疫协同作用
Zihan Yan,Xiaorong Hou,Fuquan Zhang
Zihan Yan
Jia Li,Songling Liu,Shihao Jiang et al.
Jia Li et al.
Xixi Gao,Jia Huang,Zhiying Yang
Xixi Gao
Hepatitis B virus-specific T cell receptor therapy for advanced hepatocellular carcinoma: lessons from Wu et al [0.03%]
郑荣寿等关于我国2015年癌症流行病学特征文章的述评及评论回复
Rashmi Kumar,Irina Dobrosotskaya,Timothy L Frankel
Rashmi Kumar
Evolution of minimally invasive surgery in gallbladder carcinoma: maintaining oncological radicality and the enduring value of open resection [0.03%]
胆囊癌微创手术的发展：保持根治性和开腹手术的持久价值
Tomoyuki Abe,Shintaro Kuroda,Tsuyoshi Kobayashi et al.
Tomoyuki Abe et al.
Obesity indices and type 2 diabetes risk: implications for dynamic assessment and metabolic mechanisms [0.03%]
肥胖指数与2型糖尿病风险：动态评估和代谢机制的启示
Bo Wu,Yun Chen,Haitao Xu et al.
Bo Wu et al.
Diana Berzan,Stylianos Tzedakis,Heithem Jeddou
Diana Berzan
Protein S-sulfhydration: an emerging regulatory layer with therapeutic potential in metabolic dysfunction-associated steatotic liver disease [0.03%]
蛋白质半胱氨酸硫化修饰：在代谢功能异常相关肝脂肪变性疾病中具有治疗潜力的新调控机制
Mingchang Pang,Huayu Yang
Mingchang Pang
Beyond the H-index: re-centering the operating room in the evaluation of the surgeon-scientist in hepatobiliary surgery [0.03%]
超越H指数：在肝胆手术外科科学家评估中重新重视手术室的作用
Agostino Maria De Rose
Agostino Maria De Rose
Are we ready for a molecular diagnostics-driven era in hepatobiliary surgery? [0.03%]
我们准备好迎接肝胆外科分子诊断时代了吗？
Zi-Jie Tang,Jia-Hao Xu,Li-Hui Gu et al.
Zi-Jie Tang et al.